Related Experiment Video
Updated: Jul 8, 2025
4D Multimodality Imaging of Citrobacter rodentium Infections in Mice
Published on: August 13, 2013
Exploring the potential of radiolabeled duramycin as an infection imaging probe
Anuj Kumar1,2, Jyotsna Bhatt Mitra1,2, Elina Khatoon1
1Radiopharmaceutical Division, Bhabha Atomic Research Centre, Mumbai, India.
Abstract:
The continuous pursuit of designing an ideal infection imaging agent is a crucial and ongoing endeavor in the field of biomedical research. Duramycin, an antimicrobial peptide exerts its antimicrobial action on bacteria by specific recognition of phosphatidylethanolamine (PE) moiety present on most bacterial membranes, particularly Escherichia coli (E. coli). E. coli membranes contain more than 60% PE. Therefore, duramycin is an attractive candidate for the formulation of probes for in situ visualization of E. coli driven focal infections. The aim of the present study is to develop 99m Tc labeled duramycin as a single-photon emission computed tomography (SPECT)-based agent to image such infections. Duramycin was successfully conjugated with a bifunctional chelator, hydrazinonicotinamide (HYNIC). PE specificity of HYNIC-duramycin was confirmed by a dye release assay on PE-containing model membranes. Radiolabeling of HYNIC-duramycin with 99m Tc was performed with consistently high radiochemical yield (>90%) and radiochemical purity (>90%). [99m Tc]Tc-HYNIC-duramycin retained its specificity for E. coli, in vitro. SPECT and biodistribution studies showed that the tracer could specifically identify E. coli driven infection at 3 h post injection. While 99m Tc-labeled duramycin is employed for monitoring early response to cancer therapy and cardiotoxicity, the current studies have confirmed, for the first time, the potential of utilizing 99m Tc labeled duramycin as an imaging agent for detecting bacteria. Its application in imaging PE-positive bacteria represents a novel and promising advancement.
Insights
Researchers developed a new imaging agent using technetium-99m labeled duramycin to detect Escherichia coli infections. This novel probe specifically targets bacteria, offering a promising tool for visualizing infections in situ.
Area of Science:
- Biomedical research
- Infection imaging
- Antimicrobial peptides
Background:
- Designing ideal infection imaging agents is critical in biomedical research.
- Duramycin, an antimicrobial peptide, targets bacterial phosphatidylethanolamine (PE) on membranes, especially in Escherichia coli (E. coli).
- E. coli membranes are rich in PE, making duramycin a potential candidate for infection visualization probes.
Purpose of the Study:
- To develop a technetium-99m (99mTc) labeled duramycin as a single-photon emission computed tomography (SPECT)-based agent for imaging E. coli infections.
- To assess the specificity and efficacy of 99mTc-HYNIC-duramycin for detecting bacterial infections.
Main Methods:
- Duramycin was conjugated with hydrazinonicotinamide (HYNIC), a bifunctional chelator.
- The specificity of HYNIC-duramycin for PE was confirmed using a dye release assay.
- Radiolabeling with 99mTc yielded high radiochemical purity and yield.
- In vitro specificity, SPECT imaging, and biodistribution studies were performed to evaluate the agent's performance.
Main Results:
- 99mTc-HYNIC-duramycin demonstrated retained specificity for E. coli in vitro.
- SPECT and biodistribution studies confirmed the tracer's ability to specifically identify E. coli infections 3 hours post-injection.
- The radiolabeling process achieved high radiochemical yield (>90%) and purity (>90%).
Conclusions:
- 99mTc-labeled duramycin shows significant potential as a novel imaging agent for detecting bacterial infections, particularly those caused by PE-positive bacteria like E. coli.
- This represents a novel advancement in imaging PE-positive bacterial infections.
- The study confirms the utility of 99mTc-duramycin for bacterial detection, expanding its application beyond cancer therapy monitoring.
